Abstract:

Objective To compare the efficacy and safety of sugammadex versus neostigmine for reversal ofresidual neuromuscular blockade in patients undergoing simultaneous pancreas ⁃ kidney transplantation. Methods The patients undergoing simultaneous pancreas⁃kidney transplantation from January 2017 to May 2021 were includedand divided into 2 groups：sugammadex group（group S）and neostigmine group（group N）. Demographic charac⁃teristics，effective time，spontaneous breathing recovery time，extubation time，post⁃anesthesia care unit（PACU）stay and hospital stay were recorded. The two groups were compared in terms of postoperative complications，creati⁃nine clearance rate，serum amylase and fasting blood glucose before surgery and on the 1st，3rd，7th，14th daypostoperatively. Results A total of 152 patients were enrolled：82 in group S and 70 in group N. Compared withgroup N，the effective time，spontaneous breathing recovery，extubation time and PACU stay in group S weremuch shorter. The incidences of postoperative hypoxemia and pulmonary infection of group S were much lower thangroup N（P < 0.05）. There were no statistically significant differences in the creatinine clearance rate and thelevels of serum amylase and fasting blood glucose as well as in the incidences of other postoperative complicationsbetween the two groups. Conclusions Sugammadex is better than neostigmine at promoting the reversal of residualneuromuscular blockade and lowering postoperative pulmonary complications.

Key words:

sugammadex, neostigmine, simultaneous pancreas ?kidney transplantation, respiratoryrecovery, pulmonary complications